First United States Patient Receives Neovasc's Reducer in Compassionate Use Procedure

June 25, 2018—Neovasc Inc. announced that the first United States patient has been implanted with the Neovasc Reducer for the treatment of refractory angina. The compassionate use case was conducted by Gerald Koenig, MD, along with Ryan Gindi, MD, and colleagues, of the Division of Cardiology at Henry Ford Hospital in Detroit, Michigan. The Reducer has received European CE Mark approval for the treatment of refractory angina.

In Neovasc's announcement, Dr. Koenig commented, "This patient has severe coronary artery disease and has suffered from refractory angina for a few years. The condition has had a significant impact on his quality of life during this time, with little to no relief from multiple other widely accepted treatment options."

Dr. Koenig continued, "This novel device has accumulating evidence supporting the physiologic basis and associated clinical benefit. My experience with the Reducer during the procedure was very positive. The process is similar to implanting a stent. In terms of the patient, he tolerated the procedure very well and had no complications."